Inherited Neuropathy Consortium (INC) Research Archives

CMTA and INC Forge Groundbreaking Alliance to Accelerate Comprehensive Research Across All Charcot-Marie-Tooth Disease Types

What happens when the world’s largest CMT funder joins forces with the leading clinical research network? A new era begins. Inside: the alliance changing everything.

CMTA-INC Alliance Announces 2025 Inherited Neuropathies Fellowship Recipient: Orthopedic Surgeon to Focus on Improving Outcomes for People with CMT

The CMTA–INC Alliance announced the 2025 Inherited Neuropathies Fellowship recipient, supporting clinical research focused on corrective foot and ankle care and surgical outcomes for people with CMT.

ACT-CMT: CMT1A Natural History Study, Long-Term Progression, and Biomarkers

With $1.2M in CMTA funding, the ACT-CMT study is tracking long-term CMT1A progression and advancing biomarker development to prepare for future clinical trials.

CMT2A Biomarkers and Natural History

Close-up of a hand pinching a DNA double helix between the thumb and forefinger against a bright blue sky, highlighting DNA and genetics with a scientific context.

With CMTA support of $572,055, researchers at the Inherited Neuropathy Consortium led by Michael E. Shy, MD, are working to track disease progression and identify biomarkers in CMT2A. By studying blood, skin biopsy, and MRI biomarkers alongside clinical assessments, this project aims to develop critical tools for future clinical trials and advance CMT2A research.

Building the Largest CMT Patient Data Set

Blue-tinted microscopic fibers with textured surfaces resembling chromosomes, glowing softly against a cyan background, evoking a scientific, high-tech atmosphere.

CMTA has committed $206,000 over three years to support the Inherited Neuropathy Consortium (INC) in advancing CMT research. Since September 2022, this funding has sustained 20 clinical sites, supported over 20 scientific publications, and enabled large-scale natural history studies of CMT1B and CMT1X. With more than 7,000 patients enrolled, INC’s data set is critical for future clinical trials and Investigational New Drug (IND) approvals.